ChromoGenics announce updated degree of assurance

The Board of Directors of ChromoGenics AB (“the Company”) announces today that the new issue of shares with preferential rights for the Company's existing shareholders which was announced on February 8, 2022 (the “Rights Issue”) has been secured to approximately 79.9 percent, in accordance with the communicated intention. Senior executives and board members of the Company have entered into subscription commitments and guarantee commitments for a total of approximately SEK 0.8 million, with the result that the Rights Issue is now secured at approximately SEK 54.4 million.

For more information, please contact:
Fredrik Fränding, CEO
Tel: +46(0)72 249 24 62
Lars Ericsson, CFO & Head of Communications
Tel: +46 (0)18 430 0430
E-mail: info@chromogenics.com  
ChromoGenics

About ChromoGenics
ChromoGenics is a proptech company that produces dynamic glass for real estate. The company’s product ConverLight® Dynamic, controls indoor comfort with high daylight transmission, great view and solar heat blocking and thereby reduces cost of cooling. ConverLight® Dynamic is based on a patented solution where electrochromic coatings are laminated in plastic film and then laminated between glass. The plastic film is easy to transport, so long shipments of bulky glass can be avoided. ChromoGenics also offers static glass, ConverLight® Static, and the ConverLight® Energy facade glass solution. ChromoGenics' stock was listed on Nasdaq First North Growth Market in 2017 and has supplied glass technology to several major real estate companies.

ChromoGenics originates from world-leading research at Ångströmlaboratoriet at Uppsala University. The company's production facility in Uppsala has been partially financed with conditional loans from Energimyndigheten (Energy Authority) in Sweden. ChromoGenics' share (CHRO) is listed on Nasdaq First North Growth Market with Erik Penser Bank as Certified Adviser: certifiedadviser@penser.se

IMPORTANT INFORMATION

This press release is not an offer to subscribe for units in ChromoGenics, and investors should not subscribe or acquire any securities other than on the basis of the information in the prospectus.

This press release may not be released, published or distributed, directly or indirectly, in or to the United States, Australia, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where the distribution of this press release would be illegal. This press release also does not constitute an offer to sell new shares, paid subscribed shares or subscription rights to any person in a jurisdiction where it would not be permitted to provide such an offer to such person or where such action would require additional prospectus, registration or other measures than according to Swedish law. The prospectus, the application form and other documents relating to the Rights Issue may not be distributed in or to any country where such distribution or the Rights Issue requires measures specified in the preceding sentence or where they would conflict with rules in such country.

The new shares paid subscribed shares, and subscription rights have not been registered or approved by any US federal or state securities authority or supervisory authority. No new shares, paid subscribed shares, subscription rights or other securities issued by ChromoGenics have been registered or will be registered in accordance with the United States Securities Act 1933 in force at any time or under the securities law of any state in the United States. Therefore, no new shares, paid subscribed shares, subscription rights or other securities issued by the Company may be transferred, exercised or offered for sale in the United States other than in such exceptional cases that do not require registration or through a transaction that is not covered by such registration. There is no intention to register any part of the offer in the United States, and the securities issued in the Rights Issue will not be offered to the public in the United States.

The Company has not accepted any offer to the public regarding the securities referred to in this press release in any other European Economic Area ("EEA") country than Sweden. Therefore, in other EEA Member States, the securities can only be offered to qualified investors.

This press release may only be distributed and directed to "qualified investors" (as defined in section 86 (7) of the Financial Services and Markets Act 2000) in the United Kingdom and which are (i) professional investors covered by Article 19 (5) of Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Order"), or (ii) persons covered by Article 49 (2) (a) to (d) ("High Net Value Companies" etc.) of the Order (commonly referred to as "relevant persons"). In the United Kingdom, such investment or other investment activity referred to in this press release is only available to, and directed only to, relevant persons. Any person who is not a relevant person should not act on the outside or rely on this message or any of its contents.